How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Read full story on MarketWatch
Share
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
AI disclosure

Summary

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Original reporting

Open original source

Related coverage

Read full article on MarketWatch

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.